Cancers Treated:
Specializing In:
- Cancers of the ovaries, uterus, cervix and vulva/vagina
- Surgical management of gynecologic malignancies including laparotomy, robotic and conventional laparoscopy, complex pelvic surgeries including bowel and urologic components
- Chemotherapy and clinical trials
- Primary radiation for patients unable to undergo surgery
Research Interests:
- Comprehensive care for women with gynecologic cancers
- Translational laboratory research to discover new cancer treatments
- Mentorship and education of trainees
Biography
I am a board-certified gynecologic oncologist with extensive experience as a principal investigator running a basic science laboratory concurrent with an active clinical gynecologic oncology practice including comprehensive surgical and chemotherapy care. I am committed to advancing our understanding of gynecologic cancers with the goal of improving outcomes for our patients.
Positions
Roswell Park Comprehensive Cancer Center
- Associate Professor of Oncology
- Department of Gynecologic Oncology
- Department of Pharmacology & Therapeutics
- Dr. M. Steven Piver Endowed Professorship in Gynecologic Oncology
Background
Education and Training
- 1995-2004 - PhD - Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI
- 1995-2004 - MD - Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI
Residency
- 2004 -2008 - Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI
Fellowship
- 2008 - 2011 - Gynecologic Oncology, University of Michigan, Ann Arbor, MI
Board Certification
- Obstetrics & Gynecology - American Board of Obstetrics and Gynecology
- Gynecologic Oncology - American Board of Obstetrics and Gynecology
Professional Memberships
- American Association for Cancer Research
- Society of Gynecologic Oncology
Honors & Awards
- Department of Defense Ovarian Cancer Academy
Research Overview
Clinical Trials
Featured on CancerTalk
Showing all3 of 4 CollapseView all
Publications
Nakatsuka E, Tan L, Cunneen B, Foster C, Lei YL, McLean K. Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches. Transl Oncol. 2024 Dec;50:102119. PMID 39270525 / PMC11416511.
Tondo-Steele K, Milliron KJ, Siedel JH, Uppal S, Merajver SD, McLean K. Germline genetic testing reveals pathogenic variants in uterine serous carcinoma patients. Gynecol Oncol Rep. 2024 Oct;55:101498. PMID 39297075 / PMC11408757.
Tan L, Tondo-Steele K, Foster C, McIlwain C, Bolland DE, Crawford HC, Sciallis A, McLean K. Inhibition of Tumor Microenvironment Cytokine Signaling Sensitizes Ovarian Cancer Cells to Antiestrogen Therapy. Cancers 14:4675, 2022. PMC9564160.
McLean K, Tan L, Bolland DE, Coffman LG, Peterson LF, Talpaz M, Neamati N, Buckanovich RJ:
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. Oncogene 38(9): 1576-1584, 2018. PM30305729.
Hacker KE, Bolland DE, Tan L, Saha AK, Niknafs YS, Markovitz DM, McLean K: The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival. Neoplasia 20(12): 1209-1218, 2018. PM30412857/PMC6226625.